Basically we're thinking between one year and two years, but this is based on a sample of drugs that were going off patent in 2010. Will it be the same thing in 2023? I don't know. It will be a different basket of drugs. To give you an idea, right now, this is what it would mean.
One thing I think is very important when we talk about the cost of drugs, etc., is it's not a question of saving a bit of money; for me, it is also a question of access. When you have these new breakthrough treatments against cancer, for example, fantastic, but then if we pay 25% more than European countries pay, maybe the European country will be able to accept to reimburse this drug and Canada will not be able to do that. We'll not be able to provide the same access to the same treatment because it is just too expensive in Canada.
I have a problem with a lot of patient advocacy groups that are saying, for example, that CETA is a good thing, that it is better for innovation. Many of these groups get funding from the industry itself. If you want to have better access to new treatment you need to reduce the price of the drugs. We need to get value for money. As long as we don't get value for money, for sure there will be health technology assessment in place making sure that not everything will be reimbursed at any price.